haemophilia
Roche’s haemophilia A drug shows meaningful bleed control in P3
December 7, 2017Research and Development Roche, haemophilia, pharma
Roche has unveiled new Phase 3 data for its haemophilia A treatment Helimbra (emicizumab) in patients over 12 years of …
Contaminated blood inquiry to probe thousands of deaths
July 12, 2017Medical Communications, Research and Development HCV, HIV, biotech, drugs, haemophilia, pharma, pharmaceutical
UK Government has announced that it will launch an inquiry to discover how 4,670 people were given blood infected by …
Shire and Roche haemophilia spat spills into court
July 10, 2017Sales and Marketing Roche, Shire, haemophilia
Roche released new scientific data at a conference in Berlin regarding its developmental drug in haemophilia, emicizumab, and Shire chose …
Roche haemophilia therapy cuts bleed rate by 87%
June 26, 2017Research and Development, Sales and Marketing Roche, haemophilia
Roche has revealed new data on its investigational haemophilia therapy ACE910 (emicizumab) which shows an 87% reduction in bleed rate …
‘World Hemophilia Day’ marked by release of data
April 20, 2017Medical Communications, Research and Development Roche, Shire, haemophilia
‘World Hemophilia Day’ occurred on 17 April and the day was marked by the release of data from two companies …
Death in trial of Roche’s potential blockbuster haemophilia drug
February 24, 2017Medical Communications, Research and Development Novo Nordisk, Roche, Shire, haemophilia
Roche has reported a death in the trial of its haemophilia treatment, emicizumab, that will only add to safety concerns …
Researchers develop capsule-based haemophilia treatment tech
November 30, 2016Research and Development University of Texas, haemophilia
Researchers at the University of Texas have developed a new method for treating haemophilia B which utilises a biodegradable oral …
FDA approves Shire’s haemophilia A treatment system
August 1, 2016Manufacturing and Production, Research and Development FDA, Shire, adynovate, baxject, haemophilia
Shire has announced that the Food and Drug Administration (FDA) has approved the baxject III reconstitution system for adynovate [antihemophilic …
Baxalta sues Chugai for haemophilia drug patent breach
May 11, 2016Research and Development Baxalta, Chugai, breach, court, haemophilia, infringe, infringement, patent, sue, suing
Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent …
Biogen to spin off its haemophilia business
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off
Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …
Novo unveils new research grant to mark World Haemophilia Day
April 18, 2016Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day
Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …
FDA approves Bayer haemophilia A drug Kovaltry
March 17, 2016Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound
Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …
FDA approves CSL Behring’s new haemophilia B treatment
March 7, 2016Research and Development, Sales and Marketing CSL Behring, haemophilia
The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …
Genzyme opts into Alnylam’s Thrombosis program
October 2, 2015Medical Communications, Research and Development Alnylam, Genzyme, Sanofi, haemophilia
Sanofi subsidiary Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialisation in …
Novo Nordisk invests in haemophilia with Denmark facility
May 5, 2015Manufacturing and Production, Sales and Marketing Novo Nordisk, diabetes, haemophilia, novoseven
Novo Nordisk is spending around $225 million on a new facility in Kalundborg, Denmark to produce active pharmaceutical ingredients for haemophilia …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
